Is <scp>HLA</scp> type a possible cancer risk modifier in Lynch syndrome?-Reference-Cited by-同舟云学术

Is HLA type a possible cancer risk modifier in Lynch syndrome?

Published:2022-10-14 Issue:10 Volume:152 Page:2024-2031
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Ahadova Aysel¹²^ORCID,Witt Johannes¹²,Haupt Saskia³⁴,Gallon Richard⁵,Hüneburg Robert⁶⁷,Nattermann Jacob⁶⁷,ten Broeke Sanne⁸,Bohaumilitzky Lena¹²,Hernandez‐Sanchez Alejandro¹²,Santibanez‐Koref Mauro⁵,Jackson Michael S.⁵,Ahtiainen Maarit⁹,Pylvänäinen Kirsi¹⁰,Andini Katarina⁸,Grolmusz Vince Kornel¹¹¹²,Möslein Gabriela¹³,Dominguez‐Valentin Mev¹⁴^ORCID,Møller Pål¹⁴,Fürst Daniel¹⁵¹⁶,Sijmons Rolf⁸,Borthwick Gillian M.⁵,Burn John⁵,Mecklin Jukka‐Pekka¹⁷¹⁸,Heuveline Vincent³⁴,von Knebel Doeberitz Magnus¹²^ORCID,Seppälä Toni¹⁹²⁰²¹,Kloor Matthias¹²

Affiliation:

1. Department of Applied Tumor Biology Institute of Pathology, University Hospital Heidelberg Heidelberg Germany

2. Cooperation Unit Applied Tumor Biology German Cancer Research Centre (DKFZ) Heidelberg Germany

3. Engineering Mathematics and Computing Lab (EMCL) Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University Heidelberg Germany

4. Data Mining and Uncertainty Quantification (DMQ) Heidelberg Institute for Theoretical Studies (HITS) Heidelberg Germany

5. Translational and Clinical Research Institute Newcastle University, International Centre for Life Newcastle upon Tyne UK

6. Department of Internal Medicine I University Hospital Bonn Bonn Germany

7. National Center for Hereditary Tumor Syndromes University Hospital Bonn Bonn Germany

8. Department of Genetics University Medical Center Groningen Groningen The Netherlands

9. Department of Pathology Nova Hospital Jyväskylä Finland

10. Department of Education and science Nova Hospital Jyväskylä Finland

11. Department of Molecular Genetics National Institute of Oncology Budapest Hungary

12. Hereditary Cancers Research Group Hungarian Academy of Sciences—Semmelweis University Budapest Hungary

13. Department of Surgery Ev. Krankenhaus Bethesda Hospital Duisburg Germany

14. Department of Tumor Biology Institute of Cancer Research, The Norwegian Radium Hospital Oslo Norway

15. Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg‐Hessen University Hospital Ulm Ulm Germany

16. Institute of Transfusion Medicine University of Ulm Ulm Germany

17. Faculty of Sport and Health Sciences University of Jyväskylä Jyväskylä Finland

18. Department of Surgery Nova Hospital Jyväskylä Finland

19. Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center Tampere University Hospital Tampere Finland

20. Department of Gastrointestinal Surgery Helsinki University Central Hospital Helsinki Finland

21. Applied Tumor Genomics Research Program University of Helsinki Helsinki Finland

Funder

Deutsche Forschungsgemeinschaft

Deutsche Krebshilfe

Emil Aaltosen Säätiö

Jane ja Aatos Erkon Säätiö

Suomen Lääketieteen Säätiö